Literature DB >> 31146571

2019 John Charnley Award: Increased risk of prosthetic joint infection following primary total knee and hip arthroplasty with the use of alternative antibiotics to cefazolin: the value of allergy testing for antibiotic prophylaxis.

C C Wyles1, M Hevesi1, D R Osmon2, M A Park3, E B Habermann4, D G Lewallen1, D J Berry1, R J Sierra1.   

Abstract

AIMS: The aims of this study were to characterize antibiotic choices for perioperative total knee arthroplasty (TKA) and total hip arthroplasty (THA) prophylaxis, assess antibiotic allergy testing efficacy, and determine rates of prosthetic joint infection (PJI) based on perioperative antibiotic regimen. PATIENTS AND METHODS: We evaluated all patients undergoing primary TKA or THA at a single academic institution between January 2004 and May 2017, yielding 29 695 arthroplasties (22 705 patients), with 3411 arthroplasties in 2576 patients (11.5%) having undergone preoperative allergy testing. A series of institutional databases were combined to identify allergy consultation outcomes, perioperative antibiotic regimen, and infection-free survivorship until final follow-up.
RESULTS: Among 2576 allergy-tested patients, 2493 patients (97%) were cleared to use cephalosporins. For the entire cohort, 28 174 arthroplasties (94.9%) received cefazolin and 1521 (5.1%) received non-cefazolin antibiotics. Infection-free survivorship was significantly higher among arthroplasties receiving cefazolin compared with non-cefazolin antibiotics, with 0.06% higher survival free of infection at one month, 0.56% at two months, 0.61% at one year, and 1.19% at ten years (p < 0.001). Overall, the risk of PJI was 32% lower in patients treated with cefazolin after adjusting for the American Society of Anesthesiologists (ASA) classification, joint arthroplasty (TKA or THA), and body mass index (BMI; p < 0.001). The number needed to treat with cefazolin to prevent one PJI was 164 patients at one year and 84 patients at ten years. Therefore, potentially 6098 PJIs could be prevented by one year and 11 905 by ten years in a cohort of 1 000 000 primary TKA and THA patients.
CONCLUSION: PJI rates are significantly higher when non-cefazolin antibiotics are used for perioperative TKA and THA prophylaxis, highlighting the positive impact of preoperative antibiotic allergy testing to increase cefazolin usage. Given the low rate of true penicillin allergy positivity, and the readily modifiable risk factor that antibiotic choice provides, we recommend perioperative testing and clearance for all patients presenting with penicillin and cephalosporin allergies. Cite this article: Bone Joint J 2019;101-B(6 Supple B):9-15.

Entities:  

Keywords:  Antibiotic allergy; Cephalosporin; Prostheticjoint infection; Total hip arthroplasty; Total knee arthroplasty

Mesh:

Substances:

Year:  2019        PMID: 31146571     DOI: 10.1302/0301-620X.101B6.BJJ-2018-1407.R1

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  22 in total

1.  Penicillin allergy labels drive perioperative prophylactic antibiotic selection in orthopedic procedures.

Authors:  David T Coleman; Cosby A Stone; Wei-Qi Wei; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-07-18

Review 2.  Understanding Penicillin Allergy, Cross-reactivity, and Antibiotic Selection in the Preoperative Setting.

Authors:  Shumaila Sarfani; Cosby A Stone; G Andrew Murphy; David R Richardson
Journal:  J Am Acad Orthop Surg       Date:  2022-01-01       Impact factor: 3.020

3.  Intraosseous Regional Prophylactic Antibiotics Decrease the Risk of Prosthetic Joint Infection in Primary TKA: A Multicenter Study.

Authors:  Ben Parkinson; Peter McEwen; Matthew Wilkinson; Kaushik Hazratwala; Jorgen Hellman; Heng Khan; Andrew McLean; Yash Panwar; Kenji Doma; Andrea Grant
Journal:  Clin Orthop Relat Res       Date:  2021-11-01       Impact factor: 4.755

Review 4.  New developments and future challenges in prevention, diagnosis, and treatment of prosthetic joint infection.

Authors:  Benjamin F Ricciardi; Gowrishankar Muthukrishnan; Elysia A Masters; Nathan Kaplan; John L Daiss; Edward M Schwarz
Journal:  J Orthop Res       Date:  2020-01-31       Impact factor: 3.494

Review 5.  Contemporary Strategies to Prevent Infection in Hip and Knee Arthroplasty.

Authors:  Lachlan M Batty; Brent Lanting
Journal:  Curr Rev Musculoskelet Med       Date:  2020-08

6.  Preoperative penicillin allergy testing in patients undergoing cardiac surgery.

Authors:  Jessica H Plager; Christian M Mancini; Xiaoqing Fu; Serguei Melnitchouk; Erica S Shenoy; Aleena Banerji; Laura Collier; Nivedita Chaudhary; Sharmitha Yerneni; Yuqing Zhang; Kimberly G Blumenthal
Journal:  Ann Allergy Asthma Immunol       Date:  2020-03-23       Impact factor: 6.347

7.  CORR Insights®: Antibiotic Stewardship Interventions Improve Choice of Antibiotic Prophylaxis in Total Joint Arthroplasty in Patients with Reported Penicillin Allergies.

Authors:  Paul J Duwelius
Journal:  Clin Orthop Relat Res       Date:  2021-07-01       Impact factor: 4.755

8.  Antibiotic Stewardship Interventions Improve Choice of Antibiotic Prophylaxis in Total Joint Arthroplasty in Patients with Reported Penicillin Allergies.

Authors:  Raquel Jones; Katelyn S Quartuccio; Jessica L Stern; Eric V Heintz; Kelly E Pillinger; Thomas G Myers
Journal:  Clin Orthop Relat Res       Date:  2021-07-01       Impact factor: 4.755

9.  Editor's Spotlight/Take 5: Is Patient-reported Penicillin Allergy Independently Associated with Increased Risk of Prosthetic Joint Infection After Total Joint Arthroplasty of the Hip, Knee, and Shoulder?

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2020-12       Impact factor: 4.755

10.  Is Patient-reported Penicillin Allergy Independently Associated with Increased Risk of Prosthetic Joint Infection After Total Joint Arthroplasty of the Hip, Knee, and Shoulder?

Authors:  Victor J Wu; Michael C Iloanya; Fernando L Sanchez; Charles R Billings; Michael J O'Brien; Felix H Savoie; William F Sherman
Journal:  Clin Orthop Relat Res       Date:  2020-12       Impact factor: 4.755

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.